Niemann-Pick Disease Type C

This is another type of Niemann-Pick Disease. It causes fats to build up in the liver, spleen, and brain. It usually appears in childhood or adolescence. It can cause liver problems and neurological symptoms like difficulty walking or problems with eye movements.

Condition

What people with Niemann-Pick Disease Type C report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About Niemann-Pick Disease Type C

What It Is

Niemann-Pick disease type C (NPC) is a rare inherited disease in which cells cannot move cholesterol and other fats out of lysosomes, the compartments that break down and recycle material inside cells. The trapped fats gradually damage tissues, especially the brain, liver and spleen. NPC is progressive, meaning it worsens over time, and it shortens life, although the pace varies enormously from one person to another. NPC can begin at almost any age, from before birth to late adulthood. In babies, it may first appear as prolonged newborn jaundice (yellowing of the skin and eyes) or an enlarged liver and spleen. In older children, teenagers and adults, the main problems are neurological: clumsiness and unsteady walking (ataxia), slurred speech, trouble swallowing, declining learning and memory, and seizures in about a third of people. A telltale sign is difficulty moving the eyes up and down, called vertical gaze palsy. Many people also have cataplexy, a sudden, brief loss of muscle strength set off by laughter or strong emotion. When NPC begins in adolescence or adulthood, psychiatric symptoms such as psychosis or depression often appear before the movement problems. Despite the shared name, Niemann-Pick types A and B are a different disease, caused by a missing enzyme, with different treatment. The older label type D described a group of families of French-Acadian descent in Nova Scotia who were later shown to have type C.

Causes & Risk Factors

NPC is caused by changes (variants) in one of two genes, NPC1 or NPC2, which carry the instructions for proteins that move cholesterol within cells. At least 95% of cases involve NPC1. Nothing a person or their parents did causes NPC, and no known lifestyle factor starts or worsens it. The disease is inherited in an autosomal recessive pattern: a person has NPC only when both copies of the gene, one from each parent, carry a disease-causing variant. Parents who each carry a single copy usually have no symptoms, so NPC often appears in a family with no previous history. It occurs in all ethnic groups and affects roughly 1 in 100,000 births, with a higher rate among people of French-Acadian descent in Nova Scotia. Milder, later-onset forms are thought to be underdiagnosed. Genetic counseling helps families understand who else may carry the variant and what testing options exist for future pregnancies, including testing during pregnancy and testing of embryos during in vitro fertilization.

How It's Diagnosed

Because early signs such as clumsiness, school difficulties, an enlarged spleen or psychiatric symptoms have many common causes, NPC is often recognized late. In adults, a delay of five years or more is common. Certain combinations should raise suspicion: an enlarged spleen or a history of newborn jaundice alongside neurological problems, cataplexy, or trouble moving the eyes vertically. A careful eye-movement examination is one of the most useful clues, and recognizing it shortens the delay. When NPC is suspected, the first step is usually a blood test (sometimes a urine test) for biomarkers, substances that build up when cells cannot handle cholesterol properly, such as oxysterols and certain bile acids. These tests screen well, but a few related disorders can also raise them, so the diagnosis is confirmed with genetic testing that finds disease-causing variants in both copies of NPC1 or NPC2. Occasionally a variant is hard to detect and further genetic testing is needed. A brain MRI scan is often normal or shows only general shrinkage, so it does not establish the diagnosis on its own. Once a variant is identified in a family, relatives can be tested to see whether they carry it.

Treatment Options

There is no cure for NPC, but treatment can slow the disease and ease its effects. Care works best when coordinated by a specialist center experienced in NPC, working with local clinicians, because the disease affects many body systems. Three medicines are used to slow neurological decline. Miglustat, a capsule that reduces the cell's production of certain fats, has the longest track record. In large observational studies, people with neurological NPC who took it lived longer, and it has been linked with steadier swallowing. It is approved for NPC in the European Union; in the US its label covers only Gaucher disease, another storage disorder, so its use for NPC there is off-label. Diarrhea, gas and weight loss are common side effects. Evidence that it helps when neurological symptoms begin in infancy is limited. In 2024 the US Food and Drug Administration approved two newer oral medicines for the neurological effects of NPC. Arimoclomol (Miplyffa) boosts protective proteins inside cells. It is approved for people 2 and older, only together with miglustat, because it did not show benefit on its own. In a year-long trial in children and young people already taking miglustat, those who added arimoclomol stayed roughly stable on a scale of walking, speech, swallowing and fine motor skills, while those on miglustat alone worsened. Levacetylleucine (Aqneursa), a modified form of the amino acid leucine, is approved for people weighing at least 15 kg (about 33 pounds). In a 12-week trial it produced a small improvement in walking, balance and speech compared with a placebo. Neither medicine restores lost abilities. Both may harm a developing pregnancy, so pregnancy planning and contraception are part of starting them, and arimoclomol can cause allergic reactions, usually in the first two months. Experts now suggest considering combinations of these medicines, although cost and availability often limit this. Symptom care matters just as much. It includes speech and swallowing therapy, physical and occupational therapy with mobility aids, medicines for seizures, cataplexy, muscle stiffness and drooling, and mental health care. A feeding tube placed in the stomach (gastrostomy) is discussed early, so the decision can be made calmly before swallowing becomes unsafe. Clinical trials are testing other approaches, including cyclodextrin infusions and gene-based therapies.

What to Expect

NPC follows a very different course depending on when neurological symptoms begin. When they start in infancy, the disease usually progresses quickly and survival beyond early childhood is uncommon. Children whose neurological symptoms start later in childhood are generally expected to reach adulthood, and people whose symptoms begin as adults may live for decades. Some people have only an enlarged spleen or liver for years before any neurological signs appear. For most people, walking, speech, swallowing, hand control and thinking decline gradually over the years, and needs for help with schooling or work, mobility and daily care grow over time. Swallowing deserves special attention because food or drink going into the airway can cause chest infections and weight loss. Regular follow-up, typically every 6 to 12 months, tracks the disease with NPC-specific severity scales and checks swallowing, hearing, cognition, mood, liver health and, in children, growth. Families often coordinate many specialists, and young people need a planned move from pediatric to adult services. Guidelines recommend advance care planning and access to palliative care, which focuses on comfort, respite and emotional support, alongside disease treatment rather than only at the end of life. Rare-disease organizations and the international NPC registry can connect families with experienced centers and research studies.

When to Seek Help

Ask for an evaluation, and whether NPC has been considered, when a child or adult has an unexplained enlarged spleen or liver together with clumsiness, slipping school or work performance, slurred speech, difficulty looking up or down, episodes of collapse when laughing, or psychiatric symptoms combined with movement problems. Relatives of someone with NPC can ask about genetic counseling and carrier testing. For someone already diagnosed, contact the care team soon about coughing or choking during meals, repeated chest infections or weight loss, which can mean swallowing has become unsafe; about new or more frequent seizures; and about changes in mood, behavior or thinking. Anyone taking arimoclomol who develops hives or swelling should stop it and contact the prescriber promptly, and swelling of the face or throat that makes breathing difficult needs emergency care.

Questions to Ask Your Doctor

  1. 1.At what age did the neurological symptoms begin, and what does that suggest about how the disease is likely to progress?
  2. 2.Which disease-slowing medicines make sense for us, alone or in combination, and how will we judge whether they are working?
  3. 3.How will swallowing be monitored, and when should we start talking about a feeding tube?
  4. 4.Is there an NPC specialist center we should connect with, and which other specialists and support services should be on the care team?
  5. 5.Should other family members have genetic testing, and what options exist for future pregnancies?

Last reviewed • Oct 2026

Educational content, not medical advice.